Combination therapy for head and neck cancer before surgery
Part of Cancer clinical trials.
This trial tests a combination of two or three drugs given before surgery to shrink locally advanced head and neck cancer. The goal is to see if this approach can improve outcomes for patients whose tumors have a specific protein called EGFR.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have head and neck squamous cell carcinoma that has not been treated before.
- Your tumor must test positive for EGFR (a protein) and be considered surgically removable.
- Your cancer must be at a certain stage (III, IVA, IVB) or a specific type of oropharyngeal cancer.
- You must be in generally good health (ECOG score 0 or 1).
- You must not have other serious medical conditions like active infections, heart disease, or recent major surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (one targeted therapy and one immunotherapy) plus standard chemotherapy before surgery for head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a new combination of drugs for a type of head and neck cancer that has a specific protein called EGFR. The treatment combines an antibody-drug conjugate, an immunotherapy, and standard chemotherapy. The goal is to see if this combination shrinks or controls the cancer before possible surgery.
This trial tests a combination of two drugs given before surgery for advanced mouth or throat cancer. The drugs may help shrink tumors and improve the chance of successful surgery. It is specifically for patients whose cancer has high levels of PD-L1 and EGFR proteins.
This trial tests two different drug combos—one using an EGFR-targeted therapy alone, the other adding an immunotherapy—before standard chemoradiation for locally advanced head and neck cancer. The goal is to see which approach works better without prior treatment.
This trial tests whether combining two immunotherapy drugs before surgery is better than one alone for advanced head and neck cancer. The goal is to see if the combination can shrink tumors more and improve outcomes.
This trial tests a new immunotherapy drug (pucotenlimab) combined with chemotherapy before surgery for head and neck cancer. The goal is to see if this combination shrinks the tumor and improves outcomes for patients with locally advanced disease.
Hear when a new Head and Neck Squamous Cell Carcinoma (HNSCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.